Cellect Biotechnology: Rises on starting U.S. clinical trial of ApoGraft

Quoin Pharmaceuticals

22/10/2020 15:56

** Shares of Israel-based stem cell therapy co  APOP.O  rise
2.2% to $2.11
    ** Co initiates clinical trial in the U.S. to determine
safety and tolerability of its ApoGraft technology for bone
marrow transplantations  urn:newsml:reuters.com:*:nGNX64VRND
    ** APOP says ApoGraft cell-selection technology is designed
to prevent graft-versus-host disease, an immune condition that
occurs after bone marrow transplantation
    ** Co says first trial of ApoGraft in Israel had enrolled 11
patients, while the U.S. trial will have 18 
    ** APOP shares down 4.66% YTD

 (Reporting by Lasya Priya M in Bengaluru)
 ((LasyaPriya.M@thomsonreuters.com;))